Vitespen: a vaccine for renal cancer?-Reference-Cited by-同舟云学术

Vitespen: a vaccine for renal cancer?

Published:2008-07 Issue:9633 Volume:372 Page:92-93
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Yang James C

Publisher

Elsevier BV

Subject

General Medicine

Reference6 articles.

1. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial;Wood;Lancet,2008

2. Heat shock proteins: the ‘Swiss Army Knife’ vaccines against cancers and infectious agents;Srivastava;Vaccine,2001

3. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings;Jonasch;Br J Cancer,2008

4. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer;Mazzaferro;Clin Cancer Res,2003

5. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma;Rosenberg;J Immunol,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From a Patient Advocate’s Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?;Current Oncology Reports;2018-01

2. Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma;Current Treatment Options in Oncology;2018-01

3. Specific immunotherapy in renal cancer: a systematic review;Therapeutic Advances in Urology;2016-12-19

4. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy;Future Oncology;2014-05

5. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?;Expert Review of Anticancer Therapy;2013-12